Nascent Biotech, Inc. (NBIO)

Market Cap	16.74M
Revenue (ttm)	n/a
Net Income (ttm)	-166,028
Shares Out	119.56M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,400
Open	0.128
Previous Close	0.130
Day's Range	0.128 - 0.143
52-Week Range	0.040 - 0.452
Beta	-3.07
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About NBIO

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mr. Sean Carrick
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: NBIO

Financial Performance

In 2022, NBIO's revenue was $1.00 million, an increase of 33.33% compared to the previous year's $750,000. Losses were -$470,390, -50.94% less than in 2021.